L & S Advisors’s Intellia Therapeutics NTLA Stock Holding History

L & S Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,812	Closed	-$997K	–	253
2022 Q3	$997K	Buy	+17,812	New	+$1.1M	0.18%	122
2021 Q4	–	Sell	-5,000	Closed	-$671K	–	329
2021 Q3	$671K	Buy	+5,000	New	+$757K	0.07%	219

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

L & S Advisors's NTLA Position: Q4 2022 in Review

L & S Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 17,812 shares — an estimated $997K sold.

L & S Advisors first reported a position in NTLA in Q3 2021 and held it in 2 quarters. The position peaked at $997K in Q3 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

L & S Advisors reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
L & S Advisors sold 17,812 Intellia Therapeutics shares in Q4 2022, an estimated $997K.
L & S Advisors first reported a position in Intellia Therapeutics in Q3 2021 and held it in 2 quarters.
L & S Advisors's Intellia Therapeutics position peaked at $997K in Q3 2022.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on L & S Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.